Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Roche (RHHBY) received FDA De Novo authorization for its cobas pro i 601 platform with the Ionify Gabapentin assay. The authorization adds therapeutic drug monitoring to Roche's U.S. clinical mass spectrometry menu, which includes 25-Hydroxy Vitamin D total and steroid hormone assays such as estradiol and 17-Hydroxyprogesterone. The solution combines mass spectrometry, a method for measuring substances in samples, with an automated, standardized laboratory workflow.
An FDA-authorized Predetermined Change Control Plan (PCCP) covers expansion of up to 22 additional Ionify assays on the platform as its requirements are met. These assays are not yet available and will be introduced as applicable requirements are satisfied. Roche plans to use the PCCP to accelerate future menu expansion and continues developing additional clinical mass spectrometry assays.
Positive
- Minor pointFDA De Novo authorization adds the Ionify Gabapentin assay and therapeutic drug monitoring to Roche's U.S. menu.
- Minor point. Forward-looking: it has not happened yet and may not happen.FDA-authorized PCCP provides for up to 22 additional Ionify assays; Roche plans to accelerate menu expansion.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Up to 22 additional assays are not yet available; introduction depends on meeting applicable PCCP requirements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- FDA De Novo authorization for the cobas® pro i 601 platform with Ionify® Gabapentin assay expands Roche's mass spectrometry menu into therapeutic drug monitoring.
- Designed to simplify traditionally complex testing, the solution brings the analytical capabilities of mass spectrometry together with an automated, standardized laboratory workflow.
- Roche will utilize an FDA-authorized Predetermined Change Control Plan (PCCP) to accelerate future clinical mass spectrometry menu expansion while maintaining rigorous safety and quality standards.
Mass spectrometry is widely used for clinical applications requiring highly sensitive and specific measurement, but traditional methods often involve specialized personnel and complex manual workflows. Roche is pioneering the transition of mass spectrometry from specialized reference facilities to the core laboratory, redefining complex testing into an accessible, standardized solution for routine clinical practice.
Authorized through the De Novo pathway, the Ionify® Gabapentin assay adds a therapeutic drug monitoring application to a
"Some of the best diagnostic technologies are often very complex and, in the end, don't actually reach patients," said Dan Malarek, President and CEO of Roche Diagnostics North America. "Mass spectrometry has long been valued for its analytical performance, but the complexity of traditional workflows has limited its use in routine laboratories. By automating and standardizing this technology, we're helping make sophisticated testing more accessible to laboratories, clinicians and patients who depend on reliable results."
About the cobas® Mass Spec solution
Mass spectrometry is widely regarded as a gold-standard analytical method for certain clinical applications, including steroid hormone measurement, vitamin D testing and therapeutic drug monitoring. The cobas® Mass Spec solution combines the high specificity, sensitivity and accuracy of mass spectrometry with an automated, standardized workflow designed to make this traditionally complex technology more accessible to routine clinical laboratories.
In July 2025, the cobas® Mass Spec solution received the Best New Clinical Diagnostics Instrumentation of 2024 award in the Scientists' Choice Awards® 2025, recognizing innovation in clinical laboratory technology.
For more information about cobas® Mass Spec solution, please visit go.roche.com/ClinicalMassSpec.
About Roche
Roche is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland, in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For Further Information
Roche Diagnostics U.S. Media Relations
us.mediarelations@roche.com
Amy Lynn
+1-317-750-7811
amy.lynn@roche.com
Jen Dial
+1-463-867-0232
jen.dial@roche.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/roche-receives-fda-de-novo-authorization-for-cobas-pro-i-601-platform-with-ionify-gabapentin-assay-advancing-automated-mass-spectrometry-for-routine-clinical-laboratories-302939987.html
SOURCE Roche Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.